Upchurchchoate0560

Tobacco dependence follows a chronic and relapsing course, but most treatment programmes are short. Extended care has been shown to improve outcomes. Examining use patterns for longer term programmes can quantify resource requirements and identify opportunities for improving retention.

We analyse 38 094 primary care treatment episodes from a multisite smoking cessation programme in Ontario, Canada that provides free nicotine replacement therapy (NRT) and counselling. We calculate distributional measures of weeks of NRT used, clinical visits attended and total length of care. We then divide treatment courses into four exclusive categories and fit a multinomial logistic regression model to measure associations with participant characteristics, using multiple imputation to address missing data.

Time in treatment (median=50 days), visits (median=3) and weeks NRT used (median=8) were well below the maximum available. Of all programme enrolments, 28.8% (95% CI=28.3% to 29.3%) were single contacts, 31.3% (30.8esults show that use of the nicotine patch is associated with retention in care, and that improving engagement of younger patients should be a priority.Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). Epacadostat In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional whole-body SPECT/CT imaging and venous blood sampling over 7 d. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Results 177Lu-DOTA-ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in all patients. The average retention in tumor lesions was 0.02% injected activity per gram at 6 h after injection and approximately 0.01% at 170 h after injection. In this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfaces were 4.21, 0.17, 0.36, and 1.19 Gy/GBq, respectively. The red marrow was found to be the dose-limiting organ for all patients. A median maximum tolerated injected activity of 6.0 GBq may exceed the defined threshold of 2 Gy for the red bone marrow in individual patients (4/8). Conclusion 177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.New biomarkers for metastatic prostate cancer are needed. The aim of this study was to evaluate the prognostic value of 18F-FDG PET whole-body tumor burden parameters in patients with metastatic prostate cancer who received first-line abiraterone or enzalutamide therapy. Methods This was a retrospective study of patients with metastatic castration-sensitive prostate cancer (mCSPC, n = 25) and metastatic castration-resistant prostate cancer (mCRPC, n = 71) who underwent 18F-FDG PET/CT within 90 d before first-line treatment with abiraterone or enzalutamide at a tertiary-care academic cancer center. Whole-body tumor burden on PET/CT was quantified as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and correlated with overall survival (OS) probabilities using Kaplan-Meier curves and Cox models. Results The median follow-up in survivors was 56.3 mo (interquartile range, 37.7-66.8 mo); the median OSs for patients with mCRPC and mCSPC were 27.8 and 76.1 mo, respectively (P less then 0.001). On univariate analysis, the OS probability of mCRPC patients was significantly associated with plasma levels of alkaline phosphatase (hazard ratio [HR], 1.90; P less then 0.001), plasma levels of lactate dehydrogenase (HR, 1.01; P less then 0.001), hemoglobin levels (HR, 0.80; P = 0.013), whole-body SUVmax (HR, 1.14; P less then 0.001), the number of 18F-FDG-avid metastases (HR, 1.08; P less then 0.001), whole-body metabolic tumor volume (HR, 1.86; P less then 0.001), and TLG (HR, 1.84; P less then 0.001). On multivariable analysis with stepwise variable selection, hemoglobin levels (HR, 0.81; P = 0.013) and whole-body TLG (HR, 1.88; P less then 0.001) were independently associated with OS. In mCSPC patients, no significant association was observed between these variables and OS. Conclusion In patients with mCRPC receiving first-line treatment with abiraterone or enzalutamide, 18F-FDG PET WB TLG is independently associated with OS and might be used as a quantitative prognostic imaging biomarker.Quantification of myocardial perfusion and myocardial blood flow using 82Rb PET is increasingly used for assessment of coronary artery disease. Current guidelines suggest injections of 1,100-1,500 MBq for both stress and rest. Reducing the injected dose avoids PET system saturation in first-pass flow images and reduces radiation exposure, but the impact on myocardial perfusion quantification of static perfusion images is not fully understood. In this study, we aimed to evaluate the feasibility of performing myocardial perfusion scans using either a half-dose (HfD) or quarter-dose (QD) protocol using reconstructions from acquired full-dose (FD) scans. Methods This study comprised 171 patients who underwent rest/stress 82Rb PET with a 3-dimensional 4-ring PET/CT scanner using a FD protocol and invasive coronary angiography within 6 mo of the PET emission scan. HfD and QD reconstructions were obtained using the prescribed percentage of events from the FD list-mode files. The total perfusion deficit was quantified for rest (rTPD), stress (sTPD), and ischemia (ITPD = sTPD - rTPD). Diagnostic accuracy for obstructive coronary artery disease, defined as at least 70% stenosis in any of the 3 major coronary arteries, was compared with area under the receiver-operating-characteristic curve (AUC). Results Patients with a median body mass index of 28.0 (interquartile range, 23.9-31.7) were injected with doses of 1,165 ± 189 MBq of 82Rb. For sTPD, FD and HfD protocols had similar AUCs (FD, 0.807; HfD, 0.802; P = 0.108), whereas QD had a reduced AUC (0.786, P = 0.037). There was no difference in the AUC obtained for ITPD among the 3 protocols (FD, 0.831; HfD, 0.835; QD, 0.831; all P ≥ 0.805). Conclusion HfD imaging does not affect the quantitative diagnostic accuracy of 82Rb PET on 3-dimensional PET/CT systems and could be used clinically.